Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Medical to sell Ortec's wound treatment:

This article was originally published in Clinica

Executive Summary

Teva Medical, a subsidiary of Israeli generic drug company company Teva Pharmaceutical Industries, is to promote and sell New York-based Ortec International's wound healing product OrCel in Israel. The deal is initially for 10 years, and includes a requirement for Teva to obtain regulatory approval and reimbursement of the tissue-engineered treatment for chronic wounds and other dermatological conditions in Israel. Teva is one of the world's largest generic pharmaceutical firms. OrCel is a collagenic sponge seeded with allogeneic epidermal and dermal cells.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel